Publications and Seminars

2017 Publications

  1. Musich T, Li L, Liu L, Zolla-Pazner S, Robert-Guroff M, Gorny MK. Monoclonal Antibodies to V2, V3, the CD4-binding site and gp41 HIV-1 Mediate Phagocytosis in a Dose-dependent Manner. J Virol. 2017; pii: JVI.02325-16. doi: 10.1128/JVI.02325-16. PMID: 28122974.
  2. Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S. Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. Vaccine 2017;35:1464-1473. doi: 10.1016/j.vaccine.2016.11.107. PMID: 28185743.
  3. Cheng HD, Grimm SK, Gilman MSA, Gwom LC, Sok D, Sundling C, Donofrio G, Hedestam GBK, Bonsignori M, Haynes BF, Lahey TP, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SK, Seaman MS, Bailey-Kellogg C, Ackerman ME. Fine epitope signature of HIV-1 antibody neutralization breath at the CD4 binding site. Submitted for publication.
  4. Mayr LM, Decoville T, Schmidt S, Laumond G, Klingler J, Ducloy C, Bahram S, Zolla-Pazner S, Moog C. Non-neutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity. Sci Rep 2017;7(1):12655. doi: 10.1038/s41598-017-12883-6. PMCID: PMC5627290.
  5. Powell RLR, Totrov M, Itri V, Liu S, Fox A, Zolla-Pazner S. Plasticity and epitope exposure of the HIV-1 envelope trimer. J Virol 2017;91:e00410-00417. doi: 10.1128/JVI.00410-17. PMID: 28615206.
  6. Horwitz JA, Bar-On Y, Lu C-L, Fera D, Lockhart AAK, Lorenzi J, Gazumyan A, Nogueira L, Golijanin J, Scheid J, Seaman MS, Zolla-Pazner S, Nussenzweig MC. Non-neutralizing antibodies alter the course of HIV-1 infection. Cell 2017;170:637-648.e10.  doi: 10.1016/j.cell.2017.06.048. PMID: 28757252. PMCID: PMC5554461.
  7. Upadhyay C, Zolla-Pazner S, Hioe C. Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations. Submitted for publication.
  8. Yates NL, deCamp AC, Korber BT, Liao H-X, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Munir Alam S, Montefiori DC, Tomaras GD. HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Vaccine Elicited Antibody 2 Responses and Antibody Durability. Submitted for publication.

2016 Publications

  1. Jiang X, Totrov M, Li W, Sampson JM, Williams C, Lu H, Wu X, Lu S, Wang S, Zolla-Pazner S, Kong XP. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. J Virol. 2016;90(24):11007-11019.
  2. Zolla-Pazner S. Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. AIDS. 2016;23;30(16):2551-2553.
  3. Tsukrov D, McFarren A, Morgenstern A, Bruchertseifer F, Dolce E, Gorny MK, Zolla-Pazner S, Berman JW, Schoenbaum E, Zingman BS, Casadevall A, Dadachova E. Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals. Front Med (Lausanne). 2016;26;3:41.
  4. Zolla-Pazner S, Powell R, Yahyaei S, Williams C, Jiang X, Li W, Lu S, Wang S, Upadhyay C, Hioe CE, Totrov M, Kong X. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. J Virol. 2016 Nov 28;90(24):10993-11006.
  5. von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. J Virol. 2016 10;90(13):6127-39. doi: 10.1128/JVI.00347-16.
  6. Hessell AJ, McBurney S, Pandey S, Sutton W, Liu L, Li L, Totrov M, Zolla-Pazner S, Haigwood NL, Gorny MK. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. Vaccine. 2016;34(24):2713-21. doi: 10.1016/j.vaccine.2016.04.027.
  7. McFarren A, Lopez L, Williams DW, Veenstra M, Bryan RA, Goldsmith A, Morgenstern A, Bruchertseifer F, Zolla-Pazner S, Gorny MK, Eugenin EA, Berman JW, Dadachova E. A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier. AIDS. 2016;30(4):563-72. doi: 10.1097/QAD.0000000000000968.

2016 Seminars

  • Targeting Epitopes of the HIV Envelope for Production of Protective Antibodies — Jan. 20, 2016
    • ID/GHEPI Seminar Series, Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, NY
  • HIV Research for Prevention, Chicago — Oct. 17-21, 2016
    • Abstract Review Committee
  • University of Pennsylvania Medical School — Nov., 2016
  • Mount Sinai Department of Medicine Grand Rounds —  Nov. 29, 2016
    • Mount Sinai Hospital, Hatch Auditorium, Guggenheim Pavilion, New York, NY
  • Gates Foundation Collaboration for AIDS Vaccine Development — Dec., 2016